CD274 and breast cancer: These findings are reflected in the pembrolizumab-based anti-PD-L1 immunotherapy; this approach has recently been approved by the US Food and Drug Administration (FDA) in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive BC (21).